C-Abl inhibition; a novel therapeutic target for Parkinson’s disease
Parkinson’s disease (PD) is the most prevalent movement disorder in the world. The major pathological hallmarks of PD are death of dopaminergic neurons and the formation of Lewy bodies. At the moment, there is no cure for PD; current treatments are symptomatic. Investigators are searching for neu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English English |
| Published: |
Bentham Science Publishers B.V.
2018
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/58689/ http://irep.iium.edu.my/58689/1/58689_C-Abl%20inhibition.pdf http://irep.iium.edu.my/58689/2/58689_C-Abl%20inhibition_SCOPUS.pdf http://irep.iium.edu.my/58689/3/58689_C-Abl%20inhibition_WOS.pdf |
| _version_ | 1848785159812284416 |
|---|---|
| author | Abushouk, Abdelrahman Ibrahim Negida, Ahmed Abdelsalam Elshenawy, Rasha A Zein, Hossam Hammad, Ali M Menshawy, Ahmed Mohamed, Wael Mohamed Yousef |
| author_facet | Abushouk, Abdelrahman Ibrahim Negida, Ahmed Abdelsalam Elshenawy, Rasha A Zein, Hossam Hammad, Ali M Menshawy, Ahmed Mohamed, Wael Mohamed Yousef |
| author_sort | Abushouk, Abdelrahman Ibrahim |
| building | IIUM Repository |
| collection | Online Access |
| description | Parkinson’s disease (PD) is the most prevalent movement disorder in the world. The major
pathological hallmarks of PD are death of dopaminergic neurons and the formation of Lewy bodies.
At the moment, there is no cure for PD; current treatments are symptomatic. Investigators are searching
for neuroprotective agents and disease modifying strategies to slow the progress of PD. However,
recently, due to the ignorance of the main pathological sequence of PD, many drug targets failed to
provide neuroprotective effects in human trials. Currently, a huge amount of evidence suggests the involvement
of C-Abelson (c-Abl) tyrosine kinase enzyme in the pathology of PD. C-abl plays a role in
PD pathology on the levels of parkin activation, alpha synuclein aggregation, and impaired autophagy
of toxic elements. Experimental studies showed that (1) c-abl activation is involved in neuronal death
and (2) c-abl inhibition shows neuroprotective effects and prevents dopaminergic neurons’ death. Current
evidence from experimental studies and the first in-human trial shows that c-abl inhibition holds
the promise for neuroprotection against PD and therefore, justifies the movement towards larger clinical
trials. In this review article, we discussed the role of c-abl in PD pathology and the findings of preclinical
experiments and the first in-human trial. In addition, based on the lessons of the last decade
and current preclinical evidence, we provide recommendations for future research in this area. |
| first_indexed | 2025-11-14T16:48:43Z |
| format | Article |
| id | iium-58689 |
| institution | International Islamic University Malaysia |
| institution_category | Local University |
| language | English English English |
| last_indexed | 2025-11-14T16:48:43Z |
| publishDate | 2018 |
| publisher | Bentham Science Publishers B.V. |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | iium-586892018-06-26T09:02:09Z http://irep.iium.edu.my/58689/ C-Abl inhibition; a novel therapeutic target for Parkinson’s disease Abushouk, Abdelrahman Ibrahim Negida, Ahmed Abdelsalam Elshenawy, Rasha A Zein, Hossam Hammad, Ali M Menshawy, Ahmed Mohamed, Wael Mohamed Yousef R Medicine (General) Parkinson’s disease (PD) is the most prevalent movement disorder in the world. The major pathological hallmarks of PD are death of dopaminergic neurons and the formation of Lewy bodies. At the moment, there is no cure for PD; current treatments are symptomatic. Investigators are searching for neuroprotective agents and disease modifying strategies to slow the progress of PD. However, recently, due to the ignorance of the main pathological sequence of PD, many drug targets failed to provide neuroprotective effects in human trials. Currently, a huge amount of evidence suggests the involvement of C-Abelson (c-Abl) tyrosine kinase enzyme in the pathology of PD. C-abl plays a role in PD pathology on the levels of parkin activation, alpha synuclein aggregation, and impaired autophagy of toxic elements. Experimental studies showed that (1) c-abl activation is involved in neuronal death and (2) c-abl inhibition shows neuroprotective effects and prevents dopaminergic neurons’ death. Current evidence from experimental studies and the first in-human trial shows that c-abl inhibition holds the promise for neuroprotection against PD and therefore, justifies the movement towards larger clinical trials. In this review article, we discussed the role of c-abl in PD pathology and the findings of preclinical experiments and the first in-human trial. In addition, based on the lessons of the last decade and current preclinical evidence, we provide recommendations for future research in this area. Bentham Science Publishers B.V. 2018 Article PeerReviewed application/pdf en http://irep.iium.edu.my/58689/1/58689_C-Abl%20inhibition.pdf application/pdf en http://irep.iium.edu.my/58689/2/58689_C-Abl%20inhibition_SCOPUS.pdf application/pdf en http://irep.iium.edu.my/58689/3/58689_C-Abl%20inhibition_WOS.pdf Abushouk, Abdelrahman Ibrahim and Negida, Ahmed and Abdelsalam Elshenawy, Rasha A and Zein, Hossam and Hammad, Ali M and Menshawy, Ahmed and Mohamed, Wael Mohamed Yousef (2018) C-Abl inhibition; a novel therapeutic target for Parkinson’s disease. CNS & Neurological disorders-Drug targets, 17 (1). pp. 14-21. ISSN 1871-5273 E-ISSN 1996-3181 http://www.eurekaselect.com/152890/article 10.2174/1871527316666170602101538 |
| spellingShingle | R Medicine (General) Abushouk, Abdelrahman Ibrahim Negida, Ahmed Abdelsalam Elshenawy, Rasha A Zein, Hossam Hammad, Ali M Menshawy, Ahmed Mohamed, Wael Mohamed Yousef C-Abl inhibition; a novel therapeutic target for Parkinson’s disease |
| title | C-Abl inhibition; a novel therapeutic target for Parkinson’s disease |
| title_full | C-Abl inhibition; a novel therapeutic target for Parkinson’s disease |
| title_fullStr | C-Abl inhibition; a novel therapeutic target for Parkinson’s disease |
| title_full_unstemmed | C-Abl inhibition; a novel therapeutic target for Parkinson’s disease |
| title_short | C-Abl inhibition; a novel therapeutic target for Parkinson’s disease |
| title_sort | c-abl inhibition; a novel therapeutic target for parkinson’s disease |
| topic | R Medicine (General) |
| url | http://irep.iium.edu.my/58689/ http://irep.iium.edu.my/58689/ http://irep.iium.edu.my/58689/ http://irep.iium.edu.my/58689/1/58689_C-Abl%20inhibition.pdf http://irep.iium.edu.my/58689/2/58689_C-Abl%20inhibition_SCOPUS.pdf http://irep.iium.edu.my/58689/3/58689_C-Abl%20inhibition_WOS.pdf |